elraglusib
elraglusib: sourced relationships with 1 company · 1 clinical trial tracked.
elraglusib evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could elraglusib → ACTU affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) Advanced Malignant Solid Tumor | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
Phase 1/2 Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of Elraglusib Oral Tablets in Adult Participants With Advanced Solid Tumors.
Primary endpoint: To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and dose-limiting toxicities (DLTs) of elraglusib tablets
Frequently asked questions
Which companies have sourced relationships with elraglusib?
elraglusib has dated SEC/FDA relationship records for ACTUATE THERAPEUTICS, INC..
How many clinical trials involve elraglusib?
BioSniper tracks 1 clinical trial involving elraglusib.